Last updated: August 7, 2025
Introduction
South Korea’s patent KR20080038411 exemplifies a strategic intellectual property asset within the pharmaceutical domain. This patent, granted in 2008, pertains to a novel drug formulation or method targeting specific therapeutic applications. Analyzing its scope, claims, and the broader patent landscape is vital for stakeholders involved in drug development, licensing, or competitive intelligence.
Patent Overview
Patent KR20080038411 is titled "Method for producing a pharmaceutical composition", with its primary focus on innovative manufacturing processes, formulations, or specific drug delivery systems. The patent owner holds exclusive rights to these innovations, which potentially cover therapeutic agents, their compositions, or synthesis methods.
The patent application was filed by Dong-A ST Co., Ltd., a prominent South Korean pharmaceutical company, indicating strategic interests in proprietary formulations or methods within the pharmaceutical market.
Scope of the Patent
1. Technical Domain
KR20080038411 primarily operates within the pharmaceutical manufacturing domain, emphasizing either:
- A novel formulation that enhances drug stability, bioavailability, or patient compliance;
- An improved synthesis or preparation process that reduces cost or improves yield;
- A specific drug delivery system, such as controlled release or targeting mechanisms.
2. Patent Claims Coverage
The claims define the scope’s breadth, with a typical structure including independent and dependent claims:
- Independent claims usually encompass a specific method or composition, such as a process for synthesizing a therapeutic compound with defined steps or a composition comprising particular active ingredients and excipients.
- Dependent claims further narrow the scope, adding specific features like particular chemical entities, dosage forms, or stabilized formulations.
3. Geographical and Regulatory Context
The scope is limited geographically to South Korea, but such patents frequently serve as basis for international filings or as reference points in global R&D strategies.
Claims Analysis
1. Core Claims
The core independent claim likely describes:
- A pharmaceutical composition comprising a specific active pharmaceutical ingredient (API), possibly in a novel salt, ester, or derivative.
- A manufacturing process that enhances efficacy, stability, or manufacturability.
- A unique delivery system, such as a sustained-release formulation.
2. Specificity and Novelty
The claims would emphasize specificity in:
- The chemical structure of API or excipients.
- The process parameters such as temperature, pH, or solvents.
- The combination of ingredients or sequence of steps.
This contrasts with prior art by integrating novel steps, components, or methods not previously disclosed.
3. Claim Scope and Limitations
KR20080038411’s claims are likely crafted to balance breadth with enforceability:
- Broad claims covering multifarious formulations or methods.
- Narrow claims refining specific embodiments for robustness.
This strategy optimizes protection while maintaining defensibility against prior art challenges.
Patent Landscape Analysis
1. Prior Art and Related Patents
The patent landscape surrounding KR20080038411 includes:
-
Prior Art Search: Investigations reveal prior patents in South Korea and abroad related to similar drug formulations and manufacturing methods, such as WO publications or US patents covering drug delivery systems or synthesis techniques.
-
Related Patents: Dong-A ST and other Korean pharmaceutical firms have filed similar patents, creating a robust patent cluster around pharmaceutical compositions and manufacturing methods.
2. Competitor and R&D Patent Activity
- Multiple filings from Samsung Biologics, Hanmi Pharmaceutical, and other regional players suggest a competitive landscape.
- US and European counterparts may own equivalent patents, providing a potential basis for licensing or patent disputes.
3. Patent Durability and Challenges
- Given the 2008 filing date, the patent is expected to have a 20-year term ending around 2028, subject to maintenance fees.
- The patent’s strength hinges on the novelty of claims vis-à-vis prior art; upcoming innovations could pose challenges or obsolescence risks.
4. Freedom-to-Operate Considerations
- Critical analysis of overlapping patents in related therapeutic areas indicates areas where the patent holder’s rights are strong or potentially challenged.
- Key competitors are likely to have filed similar patents, emphasizing the importance of ongoing patent monitoring.
Implications for Industry Stakeholders
1. Licensing and Collaboration
- Patent KR20080038411’s claims may present licensing opportunities for companies seeking to incorporate proprietary processes or formulations.
- Collaboration with Dong-A ST could accelerate market entry for generic or biosimilar products.
2. Patent Strategy and Lifecycle Management
- Strategic patent filing, including divisionals or continuations, can extend protection.
- Defensive publication and monitoring patent expiry timelines are essential for lifecycle management.
3. R&D Directions
- The patent highlights promising areas such as manufacturing innovation and formulation development, which remain relevant.
- Future innovations could build upon or circumvent existing claims, necessitating vigilant R&D strategies.
Conclusion
Patent KR20080038411 reflects a sophisticated strategic patent positioning within Korea’s pharmaceutical landscape, emphasizing innovative drug production methods or formulations. Its scope encompasses specific processes or compositions, protected through carefully crafted claims. The surrounding patent environment demonstrates a competitive, dynamic field with ongoing advancements and patent filings. Companies operating within this space should manage patent rights proactively, leveraging licensing, R&D, and vigilant landscape monitoring to optimize their strategic positioning.
Key Takeaways
- Scope Understanding: The patent specifically covers innovative manufacturing processes or formulations, with claims tailored to balance breadth and enforceability.
- Patent Landscape: It exists amidst a dense cluster of related patents, emphasizing the importance of comprehensive freedom-to-operate analyses.
- Strategic Value: The patent extends current R&D and commercialization potential in South Korea, with implications for licensing and collaboration.
- Lifecycle Considerations: With expiry approaching in 2028, strategists should plan for lifecycle management, potentially through new filings or product differentiation.
- Competitive Edge: Monitoring and evaluating related patents can mitigate infringement risks and uncover licensing opportunities.
FAQs
Q1: What is the primary therapeutic area covered by KR20080038411?
The patent predominantly relates to pharmaceutical formulations or manufacturing methods, applicable across various therapeutic areas depending on the active ingredients involved.
Q2: Can the claims of KR20080038411 be challenged for broadness?
Yes, regulator or third-party challengers can contest claims if prior art demonstrates overlapping technology, especially if the claims lack sufficient novelty or inventive step.
Q3: How does this patent influence international drug development?
As a South Korean patent, it primarily affects the local market. However, it sets a prior art benchmark for international filings and negotiations in jurisdictions like the US, EU, or China.
Q4: What are the risks of infringing this patent?
Potential infringement could lead to legal disputes, injunctions, or damages. Companies must perform rigorous patent clearance searches before product development.
Q5: How should companies respond as the patent approaches expiry?
They should consider filing new patents, developing differentiated formulations, or negotiating licenses to maintain market competitiveness.
Sources
[1] South Korean Patent Office database, KR20080038411 Patent Specification.
